Opinion | Published:

(Meta)analyze this: Systematic reviews might lose credibility

Nature Medicine volume 18, page 1321 (2012) | Download Citation

Doctors and regulatory agencies rely on meta-analyses when setting clinical guidelines and making decisions about drugs. However, as the number of these analyses increases, it's clear that many of them lack robust evidence from randomized trials, which may lead to the adoption of treatment modalities of ambiguous value. Without a more disciplined approach requiring a reasonable minimum amount of data, meta-analyses could lose credibility.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , et al. J. Natl. Cancer Inst. 93, 1204–1214 (2001).

  2. 2.

    , et al. Lancet 373, 1532–1542 (2009).

  3. 3.

    PLoS Med. 2, e124 (2005).

Download references

Author information

Affiliations

  1. Peter Humaidan is director of the Fertility Clinic at the Odense University Hospital in Odense, Denmark

    • Peter Humaidan
  2. Nikolaos P. Polyzos is a gynecologist at the Centre for Reproductive Medicine at the Dutch-speaking Free University of Brussels, Brussels, Belgium.

    • Nikolaos P Polyzos

Authors

  1. Search for Peter Humaidan in:

  2. Search for Nikolaos P Polyzos in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0912-1321

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing